Neurosyphilis: Still prevalent and overlooked in an at risk population.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
06
2020
accepted:
20
08
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Neurosyphilis (NS) presents with a variety of clinical syndromes that can be attributed to other aetiologies due to difficulties in its diagnosis. We reviewed all cases of NS from the "Top End" of the Australian Northern Territory over a ten-year period to assess incidence, clinical and laboratory manifestations. Patient data (2007-2016) were extracted from hospital records, centralised laboratory data and Northern Territory Centre for Disease Control records. Clinical records of patients with clinically suspected NS were reviewed. A diagnosis of NS was made based on the 2014 US CDC criteria. Results were also recategorized based on the 2018 US CDC criteria. The population of the "Top End" is 185,570, of whom 26.2% are Indigenous. A positive TPPA was recorded in 3126 individuals. A total of 75 (2.4%) of TPPA positive patients had a lumbar puncture (LP), of whom 25 (35%) were diagnosed with NS (9 definite, 16 probable). Dementia was the most common manifestation (58.3%), followed by epilepsy (16.7%), psychosis (12.5%), tabes dorsalis (12.5%) and meningovascular syphilis (8.3%). 63% of probable NS cases were not treated appropriately due to a negative CSF VDRL. Despite increased specificity of the 2018 US CDC criteria, 70% of patient in the probable NS group were not treated appropriately. The overall annual incidence [95%CI] of NS was 2.47[1.28-4.31] per 100 000py in the Indigenous population and 0.95[0.50-1.62] in the non-Indigenous population (rate ratio = 2.60 [1.19-5.70];p = 0.017). Neurosyphilis is frequently reported in the NT, particularly in Indigenous populations. Disturbingly, 60% of probable neurosyphilis patients based on the 2014 criteria, and 70% based on the 2018 criteria with were not treated appropriately. It is critical that clinicians should be aware of the diagnosis of NS and treat patients appropriately.
Sections du résumé
BACKGROUND
Neurosyphilis (NS) presents with a variety of clinical syndromes that can be attributed to other aetiologies due to difficulties in its diagnosis. We reviewed all cases of NS from the "Top End" of the Australian Northern Territory over a ten-year period to assess incidence, clinical and laboratory manifestations.
METHODS
Patient data (2007-2016) were extracted from hospital records, centralised laboratory data and Northern Territory Centre for Disease Control records. Clinical records of patients with clinically suspected NS were reviewed. A diagnosis of NS was made based on the 2014 US CDC criteria. Results were also recategorized based on the 2018 US CDC criteria.
RESULTS
The population of the "Top End" is 185,570, of whom 26.2% are Indigenous. A positive TPPA was recorded in 3126 individuals. A total of 75 (2.4%) of TPPA positive patients had a lumbar puncture (LP), of whom 25 (35%) were diagnosed with NS (9 definite, 16 probable). Dementia was the most common manifestation (58.3%), followed by epilepsy (16.7%), psychosis (12.5%), tabes dorsalis (12.5%) and meningovascular syphilis (8.3%). 63% of probable NS cases were not treated appropriately due to a negative CSF VDRL. Despite increased specificity of the 2018 US CDC criteria, 70% of patient in the probable NS group were not treated appropriately. The overall annual incidence [95%CI] of NS was 2.47[1.28-4.31] per 100 000py in the Indigenous population and 0.95[0.50-1.62] in the non-Indigenous population (rate ratio = 2.60 [1.19-5.70];p = 0.017).
CONCLUSION
Neurosyphilis is frequently reported in the NT, particularly in Indigenous populations. Disturbingly, 60% of probable neurosyphilis patients based on the 2014 criteria, and 70% based on the 2018 criteria with were not treated appropriately. It is critical that clinicians should be aware of the diagnosis of NS and treat patients appropriately.
Identifiants
pubmed: 33027255
doi: 10.1371/journal.pone.0238617
pii: PONE-D-20-18019
pmc: PMC7540903
doi:
Substances chimiques
Anti-Bacterial Agents
0
Penicillin G Benzathine
RIT82F58GK
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0238617Subventions
Organisme : Wellcome Trust
ID : 200909
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Sex Transm Dis. 2015 Jun;42(6):347-9
pubmed: 25970316
Int J Equity Health. 2013 Sep 13;12:79
pubmed: 24034417
Sex Transm Infect. 2001 Jun;77(3):214-7
pubmed: 11402234
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
pubmed: 26042815
JAMA. 1972 Feb;219(6):726-9
pubmed: 5066697
Sex Transm Dis. 2012 Apr;39(4):291-7
pubmed: 22421696
Clin Infect Dis. 2016 Nov 1;63(9):1180-1186
pubmed: 27585981
PLoS One. 2015 Dec 08;10(12):e0143304
pubmed: 26646541
BMC Psychiatry. 2016 Jul 11;16:230
pubmed: 27400713
Sex Transm Infect. 2018 Dec;94(8):585-588
pubmed: 30061192
Acta Neurol Scand. 1981 Apr;63(4):237-46
pubmed: 7211189
Sci Rep. 2017 Mar 24;7:45339
pubmed: 28338084
Eur Neurol. 2004;52(1):29-35
pubmed: 15237250
Acta Derm Venereol. 2004;84(6):459-62
pubmed: 15844637
J Neurol. 2019 Mar;266(3):616-624
pubmed: 30617996
Postgrad Med J. 1982 Nov;58(685):685-7
pubmed: 7170266